An overview of candesartan in clinical practice
- 1 August 2011
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Cardiovascular Therapy
- Vol. 9 (8) , 975-982
Abstract
(2011). An overview of candesartan in clinical practice. Expert Review of Cardiovascular Therapy: Vol. 9, No. 8, pp. 975-982.Keywords
This publication has 58 references indexed in Scilit:
- Effect of Valsartan on the Incidence of Diabetes and Cardiovascular EventsNew England Journal of Medicine, 2010
- Systolic Heart FailureNew England Journal of Medicine, 2010
- Predictors of Development of Diabetes in Patients With Chronic Heart Failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) ProgramDiabetes Care, 2009
- Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trialThe Lancet, 2008
- Telmisartan to Prevent Recurrent Stroke and Cardiovascular EventsNew England Journal of Medicine, 2008
- ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)European Heart Journal, 2008
- Effects of Candesartan Compared With Amlodipine in Hypertensive Patients With High Cardiovascular RisksHypertension, 2008
- The ACCESS StudyStroke, 2003
- Rationale for Fixed-Dose Combinations in the Treatment of HypertensionDrugs, 2002
- Clinical Pharmacokinetics of CandesartanClinical Pharmacokinetics, 2002